Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial

Ronald P. DeMatteo, Karla V. Ballman, Cristina R. Antonescu, Christopher Corless, Violetta Kolesnikova, Margaret Von Mehren, Martin D. McCarter, Jeffrey Norton, Robert G. Maki, Peter W.T. Pisters, George D. Demetri, Murray F. Brennan, Kouros Owzar

Research output: Contribution to journal › Article › peer-review

121 Scopus citations

Fingerprint

Dive into the research topics of 'Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences